Dedicated to giving hope to millions of patients with cancer by improving cell therapy.
There is a significant unmet need in T cell therapy.
T cells are a type of white blood cell and a critical part of your immune system’s defense against cancer. Cell therapies are designed to enhance a T cell’s ability to attack tumor tissue. While there has been significant progress in using T cell therapy for hematological tumors, such as lymphomas and leukemias, many existing T cell treatments cause high levels of toxicity, fail to fully eliminate tumors, and are ineffective in solid tumors.
Leveraging our TAC platform, we hope to deliver T cell therapies that are less toxic than existing T cell therapies and effective in killing both solid tumors and hematological cancers.
At Triumvira, our mission is to empower the body's immune system to conquer cancer more effectively and safely.
Our T cell Antigen Coupler (TAC) is designed to work harmoniously with your body and help it fight cancer more naturally than other methods. By using the natural T cell receptor (TCR), the receptor that binds a T cell to a tumor cell, TAC engages the T cell’s ability to self-regulate cell killing – activating for as long as necessary and stopping before it becomes toxic.
TAC can be produced in a number of ways and fine-tuned to target a wide variety of tumor types. This versatile technology has the potential to improve the quality of life for a vast range of patients with cancer.
We are developing TAC-based products focused on some of the most aggressive and difficult-to-treat cancers.
Our Manufacturing Approaches
For our patient-derived approach, we take a blood sample of a patient, extract the T cells, engineer them with our TAC technology in the Cocoon™ Manufacturing System, multiply and harvest them, and administer them back into a patient intravenously.
For our donor-derived approach, we take samples from healthy donors to create a non-gene edited cell bank with a subset of highly pure and potent T cells called gamma delta (γδ) cells. The γδ T cells are then engineered with our TAC technology, multiplied in the lab and administered intravenously to patients. This therapy can be applied more quickly than an autologous product.
Now recruiting for our first clinical trial.
A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC-T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2)